HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver

This article was originally published in The Rose Sheet

Executive Summary

Consumer products worldwide division sales are forecast to grow 8.1% in fiscal 2003, CEO Howard Bernick states during Prudential Securities consumer conference Sept. 3. The division, which includes the Alberto VO5, St. Ives and Tresemme global businesses, also is expected to achieve pretax earnings growth of 17% for the year, the exec adds. The Consumer Products Worldwide unit was created last year with the goal of bolstering the company's existing business abroad and facilitating expansion (1"The Rose Sheet" June 17, 2002, p. 5)...

You may also be interested in...



Alberto-Culver Consumer Products Worldwide Unit To Be Led By Bernick

Alberto-Culver's newly-formed Consumer Products Worldwide unit will be headed by Carol Bernick as president, the company announced June 12. Bernick is promoted from her previous role as president of the company's North American packaged goods operation

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel